Endocrine Pharmacology: Corticosteroids Including Glucocorticoids and Mineralocorticoids

Introduction and Overview

Corticosteroids constitute a pivotal class of endogenous and exogenous hormones synthesized by the adrenal cortex. Within the adrenal cortical steroidogenesis pathway, the zona fasciculata produces glucocorticoids, primarily cortisol, whereas the zona glomerulosa synthesizes mineralocorticoids, chiefly aldosterone. Synthetic analogues of these natural hormones have been harnessed for therapeutic purposes across a spectrum of inflammatory, autoimmune, metabolic, and cardiovascular disorders. Their potency and versatility render them indispensable in modern medical practice; consequently, a thorough understanding of their pharmacologic properties is essential for clinicians and pharmacists alike.

Learning objectives for this chapter include:

• Characterize the chemical and pharmacologic classification of glucocorticoids and mineralocorticoids.
• Explain receptor-mediated mechanisms underlying glucocorticoid and mineralocorticoid actions.
• Describe pharmacokinetic parameters that influence dosing strategies.
• Identify approved therapeutic indications and common off‑label uses.
• Recognize major adverse effects, drug interactions, and special patient considerations.

Classification

Drug Classes and Categories

Glucocorticoids and mineralocorticoids are commonly grouped into two pharmacologic categories based on their primary endocrine activity.

• Glucocorticoids – Exert anti‑inflammatory, immunosuppressive, metabolic, and mineralocorticoid effects, though the latter are typically weaker relative to aldosterone.
• Mineralocorticoids – Predominantly influence sodium and potassium homeostasis, water retention, and blood pressure regulation.

Within each category, synthetic derivatives are further subdivided according to their potency, duration of action, and receptor selectivity. Table 1 (conceptual) illustrates representative agents and their classification:

Agent	Class	Potency (relative to cortisol/aldosterone)	Duration (short, intermediate, long)
Hydrocortisone	Glucocorticoid	1×	Short
Prednisone	Glucocorticoid	2–4×	Intermediate
Betamethasone	Glucocorticoid	8–10×	Long
Fludrocortisone	Mineralocorticoid	≈10×	Intermediate

Chemical Classification

All corticosteroids share a common cyclopentanoperhydrophenanthrene (C₂₁) backbone. Chemical modifications at positions 6, 9, 11, 17, and 21 influence receptor affinity and metabolic stability. For example, the addition of a fluorine atom at C₉ (e.g., fludrocortisone) enhances mineralocorticoid potency, whereas a 1,2 double bond (as in prednisolone) increases glucocorticoid activity. These structural variations underpin functional diversity among synthetic analogues.

Mechanism of Action

Pharmacodynamics of Glucocorticoids

Glucocorticoids exert their effects primarily through intracellular glucocorticoid receptors (GR) located in the cytoplasm of target cells. Ligand binding induces a conformational change that facilitates dissociation from heat‑shock proteins, enabling translocation into the nucleus. Within the nucleus, the GR–ligand complex functions as a transcription factor, modulating gene expression through two principal mechanisms:

• Transactivation – Up‑regulation of anti‑inflammatory proteins such as annexin‑1, lipocortin‑1, and interleukin‑10.
• Transrepression – Suppression of pro‑inflammatory transcription factors, notably NF‑κB and AP‑1, thereby decreasing cytokine production, leukocyte adhesion, and prostaglandin synthesis.

In addition to genomic actions, glucocorticoids may modulate cellular signaling via non‑genomic pathways, including rapid activation of protein kinase C and modulation of membrane ion channels. These non‑genomic effects contribute to the swift onset of action observed with intravenous administration of certain glucocorticoids.

Pharmacodynamics of Mineralocorticoids

Mineralocorticoids bind to the mineralocorticoid receptor (MR) present predominantly in the distal nephron of the kidney, but also in vascular smooth muscle, colon, and heart tissue. Upon ligand binding, the MR–corticosterone complex translocates to the nucleus and enhances transcription of sodium reabsorption channels (ENaC) and Na⁺/K⁺‑ATPase pumps, promoting sodium retention and potassium excretion. Aldosterone is rapidly metabolized by the liver, whereas synthetic analogues like fludrocortisone exhibit increased metabolic stability, prolonging mineralocorticoid action.

Pharmacokinetics

Absorption

Glucocorticoids are generally well absorbed following oral administration, with bioavailability approaching 100% for hydrocortisone and prednisone in the fasting state. Lipophilic compounds demonstrate enhanced permeability across the gastrointestinal mucosa. Oral mineralocorticoids (e.g., fludrocortisone) exhibit bioavailability of 60–70%, influenced by hepatic first‑pass metabolism.

Distribution

All corticosteroids are highly protein‑bound, predominantly to albumin and corticosteroid‑binding globulin (CBG). The free fraction is critical for receptor interaction. Volume of distribution (V_d) varies: hydrocortisone V_d ≈ 0.4 L/kg, whereas betamethasone V_d ≈ 0.6–0.8 L/kg, reflecting increased tissue penetration of potent analogues. Lipid‑rich tissues, including the brain, adipose tissue, and liver, accumulate significant amounts of corticosteroids.

Metabolism

Hepatic metabolism predominates, involving cytochrome P450 enzymes (primarily CYP3A4) and 11β‑hydroxysteroid dehydrogenase (11β‑HSD). Prednisone is converted to prednisolone by 11β‑HSD1, while hydrocortisone is metabolized to cortisone via 11β‑HSD2. Synthetic glucocorticoids lacking metabolically labile sites (e.g., 6‑fluorination) exhibit prolonged half‑lives. Mineralocorticoids undergo oxidative and conjugative metabolism, with fludrocortisone displaying a half‑life of ≈8–12 hours.

Excretion

Renal excretion accounts for the majority of corticosteroid elimination, often as glucuronide or sulfate conjugates. Approximately 60–70% of an oral dose is recovered in urine within 24 hours. Hepatic excretion contributes minimally.

Half‑Life and Dosing Considerations

Glucocorticoid half‑lives vary from 1–4 hours (hydrocortisone) to 12–36 hours (betamethasone). The long duration of action permits once‑daily dosing for many agents. Mineralocorticoids typically have intermediate half‑lives (fludrocortisone ≈8–12 hours), requiring dosing at 8–12 hour intervals in some cases. Dose adjustments may be necessary in hepatic impairment, where reduced metabolism prolongs systemic exposure, or in renal impairment, where decreased excretion may also elevate plasma levels.

Therapeutic Uses and Clinical Applications

Approved Indications

Glucocorticoids are employed in a wide range of conditions:

• Autoimmune disorders: rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis.
• Allergic diseases: asthma, chronic obstructive pulmonary disease, allergic rhinitis.
• Inflammatory conditions: inflammatory bowel disease, psoriasis, atopic dermatitis.
• Organ transplantation: prevention of acute rejection.
• Adrenal insufficiency: replacement therapy in primary or secondary adrenal failure.

Mineralocorticoids find utility primarily in:

• Congenital adrenal hyperplasia (CAH) – deficiency of 21‑hydroxylase.
• Hypoaldosteronism – Addison’s disease, renal artery stenosis.
• Hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) after mineralocorticoid supplementation.

Off‑Label and Emerging Uses

Glucocorticoids are frequently prescribed off‑label for:

• Severe traumatic brain injury and spinal cord injury to mitigate cerebral edema.
• Refractory septic shock, though evidence remains contested.
• Neurodegenerative disorders such as Parkinson’s disease, where anti‑inflammatory benefits are explored.

Mineralocorticoids are occasionally used in the management of chronic heart failure to counteract neurohormonal activation; however, evidence supporting efficacy is limited and practice varies.

Adverse Effects

Common Side Effects

Glucocorticoid therapy frequently leads to:

• Metabolic alterations: hyperglycemia, dyslipidemia, increased appetite, weight gain.
• Musculoskeletal: osteoporosis, myopathy, muscle atrophy with prolonged use.
• Dermatologic: skin thinning, bruising, delayed wound healing, striae.
• Psychiatric: mood swings, insomnia, anxiety, euphoria.
• Gastrointestinal: gastritis, peptic ulcer disease, increased susceptibility to infections.

Mineralocorticoids commonly produce: hypernatremia, hypokalemia, hypertension, edema, and in severe cases, hypovolemic shock.

Serious and Rare Adverse Reactions

Serious complications may include:

• Infection risk: opportunistic infections, reactivation of latent tuberculosis.
• Adrenal suppression: secondary adrenal insufficiency upon abrupt cessation.
• Cardiovascular: arrhythmias, myocardial infarction, stroke.
• Ocular: cataract formation, glaucoma.
• Hepatotoxicity: cholestatic jaundice, hepatic failure (rare).

Black Box Warnings

Glucocorticoids carry a black box warning concerning the risk of severe infections, adrenal suppression, and metabolic derangements, emphasizing the necessity for vigilant monitoring and judicious dosing. Mineralocorticoids lack a formal black box warning but are cautioned against in patients with uncontrolled hypertension or congestive heart failure.

Drug Interactions

Major Drug-Drug Interactions

Glucocorticoids may alter the pharmacokinetics of concurrently administered drugs:

• Cytochrome P450 inhibition or induction (e.g., ketoconazole, rifampicin) can reduce glucocorticoid clearance, increasing systemic exposure.
• Glucocorticoids may induce CYP3A4, diminishing levels of drugs metabolized by this pathway (e.g., tacrolimus, warfarin).
• Concomitant use with anticoagulants heightens bleeding risk due to platelet dysfunction and mucosal friability.
• Administration with antidiabetic agents may mask hyperglycemia, necessitating dose adjustments.

Mineralocorticoids interact with:

• Potassium‑sparing diuretics (e.g., spironolactone, amiloride) leading to hyperkalemia.
• ACE inhibitors and ARBs, which similarly increase serum potassium.
• Nonsteroidal anti‑inflammatory drugs (NSAIDs) can blunt renal excretion of mineralocorticoids, exacerbating hypertension.

Contraindications

Contraindications for glucocorticoids include:

• Systemic fungal infections pending antifungal therapy.
• Active peptic ulcer disease unless protective agents are used.
• Severe uncontrolled diabetes without appropriate glycemic control.

Mineralocorticoids are contraindicated in:

• Patients with severe hypernatremia or uncontrolled hypertension.
• Congestive heart failure refractory to diuretic therapy.

Special Considerations

Pregnancy and Lactation

Glucocorticoids are classified as category C for pregnancy; their use is justified when maternal benefit outweighs potential fetal risk. Low‑dose regimens minimize teratogenic potential. Lactation is generally safe, though high doses may reduce milk production. Mineralocorticoids are also category C; limited data suggest minimal fetal exposure, but routine use is discouraged unless essential.

Pediatric and Geriatric Considerations

Pediatric dosing requires weight‑based calculations, with caution to avoid growth suppression in children. Geriatric patients exhibit increased sensitivity to glucocorticoid side effects, necessitating lower starting doses and careful monitoring for osteoporosis and hyperglycemia. Renal and hepatic function decline with age, affecting clearance.

Renal and Hepatic Impairment

In hepatic impairment, metabolism of glucocorticoids may be attenuated, prolonging half‑life and increasing risk of adverse effects. Dose adjustments are often required. Renal impairment primarily affects excretion of hydrocortisone metabolites; however, most synthetic glucocorticoids retain adequate clearance. Mineralocorticoids, being largely renally eliminated, may accumulate in severe renal failure, prompting dose reductions or avoidance.

Summary and Key Points

• Corticosteroids encompass glucocorticoids and mineralocorticoids, each with distinct receptor targets and clinical applications.
• Glucocorticoid action is mediated by nuclear GR complexes that modulate transcription; mineralocorticoids act via MR to regulate electrolyte balance.
• Pharmacokinetic profiles vary widely; lipophilicity, protein binding, and hepatic metabolism dictate dosing intervals.
• Therapeutic effects are counterbalanced by a spectrum of adverse events, necessitating vigilant monitoring and individualized therapy.
• Drug interactions, particularly involving CYP3A4, require careful consideration to avoid subtherapeutic or toxic exposures.
• Special populations—including pregnant patients, children, the elderly, and those with organ dysfunction—demand tailored dosing regimens and heightened surveillance.

Mastery of corticosteroid pharmacology is essential for optimizing therapeutic outcomes while mitigating risk. Continued clinical vigilance, informed by evolving evidence, will enhance patient safety and efficacy of these powerful agents.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.